Funding for this research was provided by:
Amyotrophic Lateral Sclerosis Association (039CYK, none)
Fund for Scientific Research Flanders (G.0996.14N, 1136917N)
Thierry Latran Foundation (FTL AAP2013, D.5009)
Geneeskundige Stichting Koningin Elisabeth (none)
European Research Council (340429)
Alfonso Martin Escudero
German Federal Ministry of Education and Research (FTLDc 01GI007A, MND-Net 01GI0704)
EU Joint Programme - Neurodegenerative Disease Research (JPND) network, PreFrontAls (01ED1512)
Foundation of the state of Baden-Württemberg (D.3830)
ALS League Belgium (none)
Opening the Future (none)
Laevers Fund for ALS Research (none)
Een Hart voor ALS (none)
CSL Behring (none)
Received: 13 May 2019
Accepted: 22 June 2019
First Online: 12 July 2019
Ethics approval and consent to participate
: All animal experiments were approved by the local ethical committee of the KU Leuven (P229/2013 and P229/2017), and were carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments.All patients or their relatives gave written informed consent to participate in the study, and the Ethics Committee of Ulm University gave approval for the collection and analysis of cerebrospinal fluid samples.
: Not applicable.
: The authors declare that they have no competing interests.